کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
8624857 | 1568106 | 2018 | 28 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
A comparative study of quality of life, functional and bone outcomes in osteogenesis imperfecta with bisphosphonate therapy initiated in childhood or adulthood
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
SF-36RCHIPAQONJDXAIQRQOLBMDQuality of life - کیفیت زندگیWHOQOL-Bref - WHOQOL-مختصرZoledronic acid - اسید زولدرونیکBisphosphonates - بیس فسفوناتOsteogenesis imperfecta - بیماری اختلال استخوانزایی، استئوژنز ایمپرفکتاBone mineral density - تراکم معدنی استخوانdual-energy X-ray absorptiometry - جذب اندازه گیری اشعه ایکس دوگانه انرژیFracture prevention - جلوگیری از شکستگیstandard error - خطای استانداردLumbar spine - ستون فقرات کمریinterquartile range - محدوده بین محدبMET - ملاقات کردodds ratio - نسبت شانس هاInternational Physical Activity Questionnaire - پرسشنامه فعالیت فیزیکی بین المللی
موضوعات مرتبط
علوم زیستی و بیوفناوری
بیوشیمی، ژنتیک و زیست شناسی مولکولی
زیست شناسی تکاملی
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
Bisphosphonates have been used for treatment of bone fragility disorders for over 25â¯years to increase bone mineral density (BMD). Anecdotally, bisphosphonate-treated Osteogenesis Imperfecta (OI) has a different trajectory to the natural history of untreated OI in terms of fracture incidence, quality of life and physical function, with minimal published evidence to support this clinical observation. This study describes functional outcomes of a cohort of adults with OI, stratified according to severity and treated with intravenous bisphosphonates as children. Reported outcomes included fracture incidence before and after puberty, mobility and BMD outcomes of this cohort. The cohort was compared to adults with OI who were never treated as children. All participants completed four questionnaires: a study specific questionnaire addressing fracture and treatment history, WHOQOL-BREF (quality of life), SF-36 (musculoskeletal function) and IPAQ (physical activity), and medical records were reviewed. Fifty-two adults with OI (80% response rate) completed the questionnaires; 33 of whom were treated with bisphosphonates in childhood. The childhood treated cohort had higher lumbar spine BMD than the adult treated cohort (z-scoreâ¯ââ¯0.4 at mean age 21.3â¯years versus â2.1 at mean age 40.9â¯years; pâ¯=â¯0.003). Pre-pubertal fracture incidence was reduced for all severities of OI in the childhood treated cohort (less severe OI, pâ¯=â¯0.01; more severe OI, pâ¯<â¯0.001), but post-pubertal fracture incidence was higher for less severe OI (pâ¯<â¯0.001). In less severe OI, childhood treated individuals had higher levels of physical activity (pâ¯=â¯0.004) and physical functioning (pâ¯=â¯0.01) than adult treated individuals. Incidence of scoliosis was not different between cohorts. There were no differences in quality of life scores between the two cohorts. Improvements in BMD do not appear to influence the prevalence of scoliosis. Results suggest that treatment with bisphosphonates at an earlier age improves physical activity, particularly in less severe forms of OI but may not alter quality of life.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Bone - Volume 113, August 2018, Pages 137-143
Journal: Bone - Volume 113, August 2018, Pages 137-143
نویسندگان
Andrew G. Feehan, Margaret R. Zacharin, Angelina S. Lim, Peter J. Simm,